<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160172</url>
  </required_header>
  <id_info>
    <org_study_id>113949</org_study_id>
    <nct_id>NCT01160172</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults</brief_title>
  <official_title>A Partially Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal 4-component Investigational Vaccine (GSK2392102A) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of&#xD;
      several formulations of an investigational Staphylococcal vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2010</start_date>
  <completion_date type="Actual">August 23, 2012</completion_date>
  <primary_completion_date type="Actual">August 23, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited local and general adverse events (AEs) in all subjects, in all vaccine groups.</measure>
    <time_frame>During a 7-day (day 0-6) follow up period after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events (AEs) in all subjects, in all vaccine groups.</measure>
    <time_frame>During a 30-day (day 0-29) follow up period after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any Serious Adverse events (SAE) in all subjects, in all vaccine groups.</measure>
    <time_frame>From first vaccination (Day 0) to study conclusion (Day 540)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any adverse event (AE) of specific interest in all subjects, in all vaccine groups.</measure>
    <time_frame>From first vaccination (Day 0) to study conclusion (Day 540)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological, biochemical or urinary laboratory abnormalities in all subjects, in all vaccine groups.</measure>
    <time_frame>Prior to each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological, biochemical or urinary laboratory abnormalities in all subjects, in all vaccine groups.</measure>
    <time_frame>1 day after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological, biochemical or urinary laboratory abnormalities in all subjects, in all vaccine groups.</measure>
    <time_frame>7 days after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological, biochemical or urinary laboratory abnormalities in all subjects, in all vaccine groups.</measure>
    <time_frame>29/30 days after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological, biochemical or urinary laboratory abnormalities in all subjects, in all vaccine groups.</measure>
    <time_frame>6 months after the last vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological, biochemical or urinary laboratory abnormalities in all subjects, in all vaccine groups.</measure>
    <time_frame>12 months after the last vaccine dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response to components of the Staphylococcal vaccine formulations in all subjects, in all vaccine groups.</measure>
    <time_frame>Prior to each vaccine dose, 1, 7 and 29/30 days after each vaccine dose, and 6 and 12 months after the last vaccine dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonisation with Staphylococcus aureus in all subjects, in all vaccine groups.</measure>
    <time_frame>At Screening (pre-Day 0) and at Days 0, 30, 60, 180, 210 and 540.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Infections, Staphylococcal</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Staphylococcal investigational vaccine GSK2392103A</intervention_name>
    <description>intramuscular vaccination according to protocol schedule</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Staphylococcal investigational vaccine GSK2392105A</intervention_name>
    <description>intramuscular vaccination according to protocol schedule</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Staphylococcal investigational vaccine GSK2392106A</intervention_name>
    <description>intramuscular vaccination according to protocol schedule</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Staphylococcal investigational vaccine GSK2392019A</intervention_name>
    <description>intramuscular vaccination according to protocol schedule</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>intramuscular vaccination according to protocol schedule</description>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who the investigator believes can and will comply with the requirements of&#xD;
             the protocol.&#xD;
&#xD;
          -  A male or female between 18 and 40 years of age, inclusive, at the time of first&#xD;
             vaccination.&#xD;
&#xD;
          -  Written informed consent obtained from the subject.&#xD;
&#xD;
          -  Healthy subjects as established by medical history, clinical examination and&#xD;
             laboratory assessment before entering into the study.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
&#xD;
          -  Female subjects of childbearing potential may be enrolled in the study, if the&#xD;
             subject:&#xD;
&#xD;
               -  has practiced adequate contraception for 30 days prior to vaccination, and&#xD;
&#xD;
               -  has a negative pregnancy test at Screening, and&#xD;
&#xD;
               -  has agreed to continue adequate contraception during the entire treatment period&#xD;
                  and for 2 months after completion of the vaccination series&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study vaccines&#xD;
             within 30 days preceding the first dose of study vaccine, or planned use during the&#xD;
             study period.&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs within 6&#xD;
             months prior to the first vaccine dose.&#xD;
&#xD;
          -  Any clinically significant acute or chronic, local or systemic infection, proven or&#xD;
             suspected to be caused by Staphylococcus aureus and requiring antibiotic treatment,&#xD;
             within the 6 months preceding the first vaccination.&#xD;
&#xD;
          -  Previous administration of any investigational Staphylococcus aureus&#xD;
             vaccine/antibodies.&#xD;
&#xD;
          -  History of; or current bleeding or coagulation disorder.&#xD;
&#xD;
          -  Known or suspected reaction or hypersensitivity likely to be exacerbated by any&#xD;
             component of the vaccines.&#xD;
&#xD;
          -  History of; or current autoimmune or other immune-mediated disease.&#xD;
&#xD;
          -  Administration or planned administration, of any vaccine not foreseen by the study&#xD;
             protocol within 30 days of the first dose of vaccines up to 1 month after the last&#xD;
             vaccine dose.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the last 3 months&#xD;
             preceding the first dose of study vaccine or planned administration during the study&#xD;
             period.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Any clinically relevant abnormal haematological or biochemical or urine laboratory&#xD;
             values at screening.&#xD;
&#xD;
          -  Any acute or chronic, clinically significant disease, as determined by physical&#xD;
             examination or laboratory screening tests.&#xD;
&#xD;
          -  Acute disease and/or fever at study entry.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions.&#xD;
&#xD;
          -  History of; or current alcoholism and/or drug abuse.&#xD;
&#xD;
          -  Any other condition that the principal investigator judges may interfere with study&#xD;
             findings.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>young adults</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

